Regeneron Pharmaceuticals Price Target Increased to $373.00 by Analysts at RBC Capital (REGN)
Analysts at RBC Capital upped their price objective on shares of Regeneron Pharmaceuticals (NASDAQ:REGN) from $349.00 to $373.00 in a research report issued to clients and investors on Wednesday. The firm currently has an “outperform” rating on the stock. RBC Capital’s price target indicates a potential upside of 9.48% from the stock’s previous close.
Other equities research analysts have also recently issued reports about the stock. Analysts at Roth Capital reiterated a “buy” rating on shares of Regeneron Pharmaceuticals in a research note on Tuesday. Separately, analysts at Deutsche Bank raised their price target on shares of Regeneron Pharmaceuticals from $410.00 to $425.00 in a research note on Tuesday. They now have a “buy” rating on the stock. Five equities research analysts have rated the stock with a hold rating and sixteen have issued a buy rating to the stock. The stock currently has an average rating of “Buy” and a consensus price target of $345.28.
In other Regeneron Pharmaceuticals news, Director Joseph L. Goldstein sold 2,000 shares of the stock in a transaction dated Wednesday, August 6th. The stock was sold at an average price of $331.20, for a total value of $662,400.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.
Shares of Regeneron Pharmaceuticals (NASDAQ:REGN) traded up 2.25% on Wednesday, hitting $340.69. 1,026,013 shares of the company’s stock traded hands. Regeneron Pharmaceuticals has a 52-week low of $227.64 and a 52-week high of $352.49. The stock’s 50-day moving average is $305. and its 200-day moving average is $306.1. The company has a market cap of $33.629 billion and a price-to-earnings ratio of 95.53.
Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its quarterly earnings results on Tuesday, August 5th. The company reported $2.47 EPS for the quarter, beating the Thomson Reuters consensus estimate of $2.30 by $0.17. The company had revenue of $666.00 million for the quarter, compared to the consensus estimate of $647.99 million. During the same quarter in the prior year, the company posted $1.73 earnings per share. The company’s quarterly revenue was up 45.4% on a year-over-year basis. Analysts expect that Regeneron Pharmaceuticals will post $9.97 EPS for the current fiscal year.
Regeneron Pharmaceuticals, Inc (NASDAQ:REGN) is an integrated biopharmaceutical company, which discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.